EX-10.46





 Exhibit 10.46 

***CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
  
 



 
 AND 

ROAR Therapeutics 

Commercial License Agreement 

Date: May 19, 2014 












 This Commercial License Agreement (this “Agreement”) is made effective on
May 19, 2014 (the “Effective Date”) 
 by and between 

Selexis SA, a company incorporated under the laws of Switzerland, with its registered office at 18 chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland 
 (“SELEXIS”) 

and 
 ROAR Therapeutics, a
company incorporated under the laws of [state], with its office at [***], San Diego, CA 92130 (“COMPANY”) 
 (SELEXIS and COMPANY,
collectively the “PARTIES” and, individually, a “PARTY”) 
 Preamble 

 

	A.	 WHEREAS, COMPANY is a biopharmaceutical company engaged in the research, development,
manufacturing and sale of biopharmaceutical products; 


  

	B.	 WHEREAS, SELEXIS is a biotechnology company engaged in the development and sale of recombinant
cell lines based on the SELEXIS Technology; 


  

	C.	 WHEREAS, SELEXIS is the owner of certain Confidential Information, the SELEXIS Know-How and the SELEXIS Patent Rights; 


  

	D.	 WHEREAS, pursuant to a services agreement between SELEXIS and PacificGMP dated May 21, 2012
(the “Services Agreement”) SELEXIS has developed certain recombinant cell line(s) and/or SELEXIS Material using the SELEXIS Technology and COMPANY and PacificGMP have evaluated such cell line(s); 



 

	E.	 WHEREAS, PacificGMP has agreed to assign to COMPANY all rights obtained by PacificGMP under the Services
Agreement, including the rights to obtain a license to commercialize products manufactured using the cell line(s) developed under the Services Agreement; and 


  


	F.	 WHEREAS, SELEXIS is willing to grant COMPANY, and COMPANY is willing to receive from SELEXIS, a
license under the SELEXIS Know-How and the SELEXIS Patent Rights with respect to the SELEXIS Technology to use the cell line(s) developed under the Services Agreement, on the terms and conditions set forth in
this Agreement. 


 Now, THEREFORE, the PARTIES agree as follows: 













	1.	 Definitions 



In addition to the terms defined above, the following terms, whether used in the singular or plural, shall have the following meanings as used in this
Agreement, unless otherwise specifically indicated: 
  

	1.1.	 “Affiliate” shall mean any Person that, as of the Effective Date, directly or
indirectly, controls, is controlled by, or is under common control with the relevant Person. For the purposes of this definition only, “control” shall mean the possession, directly or indirectly, of the power to cause
the direction of the management and policies of a Person, whether through ownership of voting securities of such Person, by contract or otherwise. A Person shall only be considered an Affiliate for so long as such Control exists.



  

	1.2.	 “BLA” shall mean a Biologic License Application for the Final Product filed with
the FDA or any comparable filing made with a Regulatory Authority in another country. 


  

	1.3.	 “Calendar Quarter” shall mean, for each Calendar Year, each of the three month
periods ending March 31, June 30, September 30 and December 31 respectively. 


  

	1.4.	 “Calendar Year” shall mean the period commencing on January 1 and ending
twelve (12) consecutive calendar months later on December 31. 


  

	1.5.	 “Cell Line” shall mean a mammalian cell line that is developed using the SELEXIS
Technology. Cell Line shall include, without limitation, any COMPANY Cell Line(s). 


  

	1.6.	 “Clinical Trials” shall mean human studies designed to measure the safety and/or
efficacy of the Product. Clinical Studies include Phase I Clinical Trials, Phase II Clinical Trials, and Phase III Clinical Trials. 


  

	1.7.	 “Collaboration Partner” shall mean a Third Party with which COMPANY collaborates
on the development of the production process and/or commercialization of a Product or to which COMPANY has granted a license for the development of the production process and/or commercialization of a Product. 



 

	1.8.	 “Combination Product Adjustment” shall mean the adjustment of: Net Sales for any
combination product done by multiplying actual Net Sales of such combination product by the fraction A/(A + B) where A is the weighted (by sales volume) average invoice price of the Product, if sold separately, and B is the weighted (by sales
volume) average invoice price of any other active ingredient, device or component in the combination, if sold separately. If, on a country-by-country basis, the other
active ingredient, device or component in the combination is not sold separately, Net Sales shall be calculated by multiplying actual Net Sales of the combination product in such country by the fraction A/C where A is the invoice price of the
Product, if sold separately, in such country and C is the invoice price of the combination product in such country. 


  

	1.9.	 “Commercial License” shall have the meaning set out in Article 2.1.




  
 3 














	1.10.	 “Commercial License Option” shall mean the option granted to Company in the
Services Agreement to obtain a non-exclusive commercial license. 


  

	1.11.	 “COMPANY Technology” shall mean any Technology owned or controlled by COMPANY,
including, without limitation, any such Technology related to License or Final Product, but excluding any SELEXIS Technology related thereto. 


  

	1.12.	 “COMPANY Cell Line” shall mean the mammalian cell line developed by SELEXIS and
provided to PacificGMP and/or COMPANY pursuant to the Services Agreement and any progeny or derivatives thereof. 


  

	1.13.	 “Confidential Information” shall mean any technical and business information
pertaining to materials and production techniques, products, processes and services, including without limitation physical working models and samples of the products, research, development, patentable and unpatentable inventions, manufacturing,
purchasing and product development plans, forecasts, strategies and information, engineering, marketing, merchandising, selling, customer lists, customer prospects, software codes, algorithms, names and expertise of employees and consultants,
blueprints, technical information, trade secrets or know-how or other related proprietary business information and data, in any case whether such information is provided in tangible or intangible form,
written, oral, graphic, pictorial or recorded form or stored on computer discs, hard drives, magnetic tape or digital or any other electronic medium. Confidential Information disclosed in any tangible format will be labeled
“Confidential” or words to similar effect, and all non-tangible disclosures will be declared to be “Confidential” or words to similar effect at the time of disclosure.
Confidential Information shall include any and all material and data created by the receiving party based on, containing or otherwise reflecting Confidential Information. Confidential Information shall also include any such information or documents
which may be disclosed hereunder which the disclosing party received in confidence from a Third Party. 


  

	1.14.	 “Contract Manufacturing Organization” shall mean an entity of which at
least fifty percent (50%) of the business is directed toward the provision of services or products for non-affiliate third parties. 



 

	1.15.	 “Contractor” shall mean a Third Party contractor who: (i) develops the
production process for Products by or on behalf of COMPANY or (ii) manufactures and supplies Products by using such production process by or on behalf of Company. 



 

	1.16.	 “Default” shall have the meaning set out in Article 9.2. 



 

	1.17.	 “Defaulting Party” shall have the meaning set out in Article 9.2.



  

	1.18.	 “FDA” shall mean the United States Food and Drug Administration, or any
successor agency. 


  

	1.19.	 “Final Product” shall mean any pharmaceutical preparation in final form
containing any Licensed Products for sale by prescription, over-the-counter or any other method, in any dosage form, formulation, presentation, line extension or package
configurations, including without limitation such Product in development where the context so requires in this Agreement. 



  
 4 














	1.20.	 “First Commercial Sale” shall mean, with respect to any Final Product in any
country, the first sale of such Final Product for use or consumption by the general public in such country after Regulatory Approval as well as Pricing and Reimbursement Approval for such Final Product has been obtained in such country. For the
avoidance of doubt, sales prior to receipt of all Regulatory Approvals and Pricing and Reimbursement Approvals necessary to commence regular commercial sales, such as so-called “treatment IND sales”,
“named patient sales” and “compassionate use sales”, shall not be construed as a First Commercial Sale. 


  

	1.21.	 “Force Majeure” shall mean conditions beyond the control of a PARTY, including
without limitation, an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of facilities or materials by
fire, earthquake, storm or the like catastrophe, and failure of plant or machinery (provided that such failure could not have been prevented by the exercise of skill, diligence and prudence that would be reasonably and ordinarily expected from a
skilled and experienced person engaged in the same type of undertaking under the same or similar circumstances). 


  

	1.22.	 “IND” shall mean an Investigational New Drug Application for the Product filed
with the FDA or any comparable filing made with a Regulatory Authority in another country. 


  

	1.23.	 “Insolvent Party” shall have the meaning set out in Article 9.3.



  

	1.24.	 “Invention” shall mean any invention, idea, innovation, enhancement, improvement
or feature, whether or not patentable or registrable, together with any intellectual property rights relating thereto (including without limitation the Patent Rights and rights to confidentiality and proprietary information). 



 

	1.25.	 “Know-How” shall mean information in
whatever form, tangible or intangible and on whatever medium, including without limitation, information and materials relating to Inventions and other know-how, trade secrets, data (including without
limitation all data from pre-clinical and clinical studies and other studies intended for regulatory submission), results, formulae, DNA and amino acid sequence information and developments.



  

	1.26.	 “Licensed Field of Use” shall mean the development, manufacture and sale of
Final Products for any field of use. 


  

	1.27.	 “Licensed Product” shall mean the recombinant protein listed in Exhibit 2.



  

	1.28.	 “Losses” shall mean all and any liability, damage, loss or expense.



  

	1.29.	 “Net Sales” shall mean the amount collected by COMPANY, its Affiliates and/or
its sublicensees on account of sales of Final Product to Third Parties in the Territory, less the following deductions: 



  
 5 














	 	(i)	 sales and excise taxes and duties paid or allowed by the selling PARTY and any other governmental charges
imposed upon the production, importation, use or sale of the Final Products; 


  

	 	(ii)	 customary trade, quantity and cash discounts allowed on Final Products; 



 

	 	(iii)	 compulsory government rebates; 



 

	 	(iv)	 allowances or credits to customers on account of rejection or return of Final Product or on account of
retroactive price reductions affecting the Final Product; 


  

	 	(v)	 freight and insurance costs, if they are included in the selling price for the Final Product invoiced to Third
Parties, provided always that such deduction shall not be greater than the balance between the selling price actually invoiced to the Third Party and the standard selling price which would have been charged to such Third Party for such Final Product
exclusive of freight and insurance in the respective country or in a comparable country; and 


  

	 	(vi)	 in the event that a Final Product is sold in any country in the form of a combination product containing one or
more other therapeutically active ingredients, the Net Sales for any such Final Product shall be computed using the Combination Product Adjustment for such country. 



 

	1.30.	 “Non-Defaulting Party” shall have the
meaning set out in Article 9.2. 


  

	1.31.	 “Notice of Default” shall have the meaning set out in Article 9.2.



  

	1.32.	 “Patent Rights” shall mean any and all of the following: (i) patent
applications (including without limitation provisional patent applications) and patents (including without limitation the inventor’s certificates); (ii) any substitution, extension (including without limitation patent term extensions and
supplementary protection certificates), registration, confirmation, reissue, continuation, divisional, continuation-in-part,
re-examination, renewal, patent of addition or the like thereof or thereto; (iii) any foreign counterparts of any of the foregoing; and (iv) any utility model applications and utility models (whether
or not corresponding to any of the foregoing). 


  

	1.33.	 “PacificGMP” shall mean PacificGMP, a company incorporated under the laws of
State of California, with its registered office at 8810 Rehco Road, Suite E, San Diego, CA 92121 USA. 


  

	1.34.	 “Person” shall mean an individual, a partnership, a joint venture, a
corporation, a limited liability company, a trust, an estate, an unincorporated organization, or any other entity, or a government or any department or agency thereof, whether acting in an individual, fiduciary or other capacity.



  

	1.35.	 “Phase I Clinical Trial” shall mean a Clinical Trial conducted in humans which
is principally intended to obtain data on the safety, tolerability, pharmacokinetic or pharmacodynamic properties of a product. Phase I shall be deemed to have been initiated 



  
 6 














	 	
when the first patient in the study has been treated. Phase I shall be deemed to have completed when the last patient has completed his or her treatment being investigated by that Clinical Trial
as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed for the primary endpoint. 

  

	1.36.	 “Phase II Clinical Trial” shall mean a Clinical Trial conducted in humans in
which a primary objective is a preliminary determination of therapeutic efficiency and/or to find an optimal dose range in patients with the disease target being studied. Phase II shall be deemed to have been initiated when the first patient in the
study has been treated. Phase II shall be deemed to have completed when the last patient has completed his or her treatment being investigated by that Clinical Trial as described in its protocol, the database is locked, and data from all patients,
according to protocol, has been analyzed for the primary endpoint. 


  

	1.37.	 “Phase III Clinical Trial” shall mean a Clinical Trial conducted in humans in
which a primary objective is a determination of therapeutic efficiency in patients with the disease target being studied. Phase III shall be deemed to have been initiated when the first patient in the study has been treated. Phase III shall be
deemed to have completed when the last patient has completed his or her treatment being investigated by that Clinical Trial as described in its protocol, the database is locked, and data from all patients, according to protocol, has been analyzed
for the primary endpoint. 


  

	1.38.	 “Price and Reimbursement Approval” shall mean any approvals, licenses,
registrations or authorizations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary to determine or set the pricing of a Product, and/or its
reimbursement level by the relevant health authorities, providers or other funding institutions, at supranational, national, regional, state or local level. 


  

	1.39.	 “Regulatory Approval” shall mean any approvals, licenses, registrations or
authorizations of any supranational, national, regional, state or local Regulatory Authority or other regulatory agency, department, bureau or governmental entity, necessary for the manufacture, marketing or sale of a Product or conduct of Clinical
Trials in a regulatory jurisdiction, excluding Price and Reimbursement Approval. 


  

	1.40.	 “Regulatory Authority” shall mean (i) the FDA or (ii) any and all
governmental or supranational agencies, ministries, authorities or other bodies with similar regulatory authority with respect to approval or registration of pharmaceutical or biologic products in any other jurisdiction anywhere in the world.



  

	1.41.	 “Royalty Term” shall mean with respect to each Final Product sold in a
particular country, the period beginning on the date of the First Commercial Sale in such country and terminating on [***]. 


  

	1.42.	 “SELEXIS Know-How” shall mean
SELEXIS’ Confidential Information and Know-How owned, controlled by SELEXIS, or to which SELEXIS has received a license which includes a right to grant sublicenses consistent with the Commercial License
relating to, 



  
 7 














	 	
without limitation, the construction and development of recombinant cell lines for the manufacture of biopharmaceutical products and existing as of the Effective Date or obtained thereafter
during the Term. 

  

	1.43.	 “SELEXIS Materials” shall mean the materials provided by SELEXIS to COMPANY
under this Agreement and all modifications and improvements thereof made by SELEXIS during the Term. 


  

	1.44.	 “SELEXIS Patent Rights” shall mean Patent Rights which: (i) are owned or
controlled by SELEXIS, or to which SELEXIS has received a license which includes a right to grant sublicenses consistent with the Commercial License (ii) are necessary or useful for the use of SELEXIS Materials or the construction, development
and use of Cell Lines and (iii) are existing as of the Effective Date or obtained thereafter during the Term. Without limiting the generality this Article, the SELEXIS Patent Rights as of the Effective Date are listed in Exhibit 1 hereto.



  

	1.45.	 “SELEXIS Technology” shall mean the SELEXIS Patent Rights, the SELEXIS Know-How and the SELEXIS Materials. 


  

	1.46.	 “Tax Authority” shall mean the relevant governing tax authority as defined in
Article 4.2. 


  

	1.47.	 “Taxes” shall mean all excises, taxes and duties with the exception of VAT.



  

	1.48.	 “Technology” shall mean all inventions (whether or not patentable or patented)
and intellectual property rights therein, including without limitation, patents, patent applications, know-how, trade secrets, copyrights, trademarks, designs, concepts, registered and unregistered design
rights, data, work product, results, reports, improvements, business and research plans, analytic methods and results, experimental methods and results, manufacturing processes, developments, technologies, technical information, composites of genes
and gene constructs, cell lines, manuals, standard operating procedures, instructions and specifications. 


  

	1.49.	 “Term” shall have the meaning set out in Article 9.1. 



 

	1.50.	 “Territory” shall mean the entire world. 



 

	1.51.	 “Third Party” shall mean a Person other than SELEXIS, COMPANY or an Affiliate of
SELEXIS or COMPANY. 


  

	1.52.	 “Transferee” shall have the meaning set out in Article 2.3.



  

	1.53.	 “Valid Claim” shall mean any issued or granted claim of the SELEXIS Patent
Rights that has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, that is unappealable or remains unappealed at the end of the time allowed for appeal, or that has not
been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 



  
 8 














	1.54.	 “VAT” shall mean value added tax and any other similar turnover, sales or
purchase, tax or duty levied by any other jurisdiction whether central, regional or local. 


  

	2.	 Commercial Licenses 



 

	2.1.	 Commercial Licenses. Subject to payment by COMPANY of the amounts provided for below and COMPANY’S
compliance with the other terms and conditions of this Agreement, SELEXIS hereby grants to COMPANY a non-exclusive license under the SELEXIS Patent Rights and SELEXIS
Know-How, in the Territory, with the limited right to sublicense in accordance with Article 2.2, to use Cell Lines and SELEXIS Materials for the manufacture of Licensed and/or Final Products in the Licensed
Field of Use and to make, have made, use, offer for sale, sell, import and otherwise exploit Final Products, including, without limitation, the use of Licensed and Final Products in Clinical Trials (the “Commercial License”).



  

	2.2.	 Sublicenses. COMPANY may, with prior written consent from SELEXIS, which consent will not be
unreasonably withheld, grant sublicenses under the Commercial License to a Contractor or to a Collaboration Partner (the “Sublicensees”) and only with respect to (i) the establishment of a production process for a
Licensed or Final Product for or on behalf of COMPANY or (ii) the manufacture, distribution or sale of a Licensed or Final Product for or on behalf of COMPANY. Notwithstanding the foregoing, for any such Sublicensee which will be only
distributing and/or selling Licensed or Final Product and which will not be receiving any Cell Line or any SELEXIS Materials or SELEXIS Know-How (or given access to any of the foregoing), COMPANY may grant
such sublicense on prior written notice to SELEXIS. Any sublicense granted under this Agreement shall require that the Sublicensees adhere to all relevant provisions of this Agreement. Notwithstanding the above, COMPANY is and remains fully liable
and responsible for any breach of this Agreement committed or any Losses caused by any Sublicensee, or any other Third Party or Affiliate to whom the Cell Lines, SELEXIS Materials and the SELEXIS Know-How or
parts thereof are made available under any such sublicense. 


  

	2.3.	 Transfer of SELEXIS Materials. COMPANY shall not transfer the Cell Lines, SELEXIS Materials or SELEXIS Know-How to any Third Party, except that during and for the Term only, COMPANY may transfer SELEXIS Know-How to Contractors or Collaboration Partners (the
“Transferees”) solely for their use in connection with their performance of the manufacturing of Products in the Licensed Field of Use with, or on behalf of, COMPANY. If COMPANY makes any such transfer, it shall notify
SELEXIS within 30 days of any such transfer and report the name and address of any Transferee together with confirmation that the Transferee has agreed in writing to adhere to the confidentiality obligations and use restrictions set out in this
Agreement. 


  

	3.	 Consideration 



 

	3.1.	 Payments. Subject to Article 3.6, COMPANY shall pay to SELEXIS the amounts as set forth below.




  
 9 














	3.1.1.	 Commercial License Execution Payment. As partial consideration for the rights and licenses granted by
SELEXIS to COMPANY under this Agreement, COMPANY shall pay SELEXIS a one-time fee of [***], due upon execution of this Agreement. 



 

	3.1.2.	 Commercial License Milestone Payments. As partial consideration for the rights and licenses granted by
SELEXIS to COMPANY under this Agreement, COMPANY shall make the following milestone payments to SELEXIS with respect to the first occurrence of each such milestone event for each Licensed Product: 



 

	 	(i)	 upon initiation of the first Phase II Clinical Trial for the first Final Product containing Licensed Product:
[***]; 


  

	 	(ii)	 upon completion of the first Phase II Clinical Trial for the first Final Product containing the Licensed
Product: [***]; 


  

	 	(iii)	 upon filing of BLA for the first final Product containing the Licensed Product: [***]; and



  

	 	(iv)	 upon First Commercial Sale of the first Final Product containing Licensed Product: [***].



  

	3.1.3.	 Commercial License Royalty Payments: In addition to the milestone payments under Article 3.1.2, during
the Royalty Term COMPANY shall pay SELEXIS on a Product-by-Product and country-by-country
basis a royalty of [***]percent ([***]%) of Net Sales of all Final Products sold worldwide. Where royalties are due for the sale of Final Products directly by COMPANY such royalties shall be paid for each Calendar Quarter within thirty
(30) days of the end of that Calendar Quarter. Where royalties are due for the sales of Final Product by a Sublicensee, payment shall be made within forty-five (45) days of the end of that Calendar Quarter. For the avoidance of doubt, no
royalty payments shall be due for a Final Product in a specific country after the Royalty Term has expired for such Final Product in such country. Where royalties are no longer due in accordance with the foregoing, the Commercial License granted to
COMPANY under this Agreement shall become perpetual, irrevocable, fully paid up and royalty free with respect to such Final Product in such country. 


  

	3.2.	 Mechanism of Payment. The payments due to SELEXIS under this Agreement shall be made by wire transfer or
electronic fund transfer to the credit and account of SELEXIS as follows: 


 Bank Name:     [***] 

Account:          [***] 

To:                   Selexis S.A. 18, 

                       
  chemin des Aulx 

                       
  1228 Plan-les-Ouates 

                       
  Geneva, Switzerland 

  
 10 














	3.3.	 Payment Terms. Except with respect to royalties due pursuant to Article 3.1.3, COMPANY shall make
payments due to SELEXIS under this Agreement at the latest [***] business days after receipt of invoice. All fees and payments, including without limitation under Article 3.1.3, do not include any applicable VAT or Taxes. 



 

	3.4.	 Records. COMPANY and its Affiliates and Sublicensees shall keep true accounts of Net Sales of Licensed
Products and COMPANY shall deliver to SELEXIS at the same time as the payments due under Article 3.1.3. a written account, including quantities of Net Sales of each such Licensed Product, broken down on a country-by-country basis with respect to those payments. SELEXIS is entitled to have such accounts audited by an independent expert of its choice. Such independent expert shall be bound by confidentiality
terms at least as restrictive as the terms of Article 8 and shall be authorized to disclose to SELEXIS only the results of its audit. COMPANY shall provide access to all information reasonably requested by such expert. The cost of any audit shall be
borne by SELEXIS unless the audit shows that COMPANY underpaid SELEXIS by more than 2% of the amounts due in which case the cost of the audit shall be borne by COMPANY. 



 

	3.5.	 Single Royalty and Milestone. For Final Products covered by more than one SELEXIS Patent Rights, COMPANY
will make one payment to SELEXIS for royalties on any unit of Final Product sold by COMPANY or Sublicensees, irrespective of how many SELEXIS Patent Rights may cover such Final Product. Each milestone described in Article 3 shall be payable only
once in relation to each Licensed Product, irrespective of the number of Final Products which incorporate that Licensed Product and undergo the events triggering the payment. All fees and payments, including without limitation under Article 3.1, do
not include any applicable VAT or Taxes. 


  

	3.6.	 Buy-Out Option. COMPANY may choose to replace certain of the
milestone payments and royalty payments as set forth in Article 3.1 in its discretion. If COMPANY so chooses, it will notify SELEXIS in writing of its decision at any time prior to the first filing of BLA for the first final Product containing the
Licensed Product. Thereafter, prior to or immediately upon filing of the first BLA for the first Final Product containing the Licensed Product, COMPANY will make a one time, non-refundable payment to SELEXIS
of [***]. Subject to the receipt of the notice set forth above in this Article, and the receipt by SELEXIS of the foregoing payment, COMPANY shall be relieved of its obligations to pay the milestone payments set forth in Articles 3.1.2(iii) and
3.1.2(iv), and the royalties as set forth in Article 3.1.3. For purposes of clarification, the foregoing will not relieve COMPANY from its obligation to pay any amounts when due as set forth in Articles 3.1, 3.1.2(i), and 3.1.2(ii), nor will it
entitle COMPANY to any refund of such amounts. If COMPANY fails to so notify SELEXIS in writing, then the original terms as set forth in Article 3.1 will apply. 



 

	4.	 Taxes 


  

	4.1.	 General. All Taxes levied on account of any payment made by COMPANY to SELEXIS pursuant to this
Agreement (other than Taxes on income, gains or profits levied against SELEXIS by any competent Swiss tax authority) will be the responsibility of, and shall be paid by, COMPANY pursuant to Article. 



  
 11 














	4.2.	 Character of Payments. The PARTIES agree that, for purposes of determining the applicability of any
Taxes, the payments to be made under this Agreement constitute payments for tangible property and license of intellectual property. However, in the event that the governing tax authority (the “Tax Authority”) qualifies
differently such payment, any additional taxes that may be applied (including without limitation any interests and penalties that may be unpaid) shall be paid by COMPANY. 



 

	4.3.	 Withholding by COMPANY. 



 

	 	(i)	 All payments by COMPANY hereunder shall be made in full without any deduction or withholding whatsoever and
free and clear of and without any deduction or withholding for or on account of any Taxes, except to the extent that any such deduction or withholding is required by law in effect at the time of payment. Subject to paragraph (ii) of this
Article, if any Taxes or amounts with respect to Taxes must be deducted or withheld, or any other deductions or withholdings must be made, from any amounts payable or paid by COMPANY, COMPANY shall pay such additional amounts as may be necessary to
ensure that SELEXIS receives and retains (after any deduction or withholding with respect to such additional amount) a net amount equal to the full amount which it would have received had payment not been made subject to Taxes or any other deduction
or withholding. 


  

	 	(ii)	 COMPANY is not required to pay any additional amounts pursuant to paragraph (i) of this Article with
respect to any deduction or withholding which would not have been required if SELEXIS had completed a declaration, claim, exemption or other form, subject to reasonable commercial efforts. 



 

	5.	 Intellectual Property 



 

	5.1.	 Ownership. Each PARTY shall retain all right, title and interest in and to its Inventions and Know-How which exist on the Effective Date or which are thereafter developed independently of the performance of this Agreement. 



 

	5.2.	 COMPANY and SELEXIS Inventions. Any Invention developed hereunder by or for either Party, solely or
jointly with the other PARTY or any Affiliate or agent thereof, shall belong exclusively (i) to COMPANY, to the extent it relates specifically to any COMPANY Technology, including, without limitation, any improvement or modification thereto
(“COMPANY Invention”); or (ii) to SELEXIS, to the extent it relates specifically to any SELEXIS Technology, including, without limitation, any improvements or modifications thereto (“SELEXIS
Invention”). Any SELEXIS Inventions shall be included within the scope of the SELEXIS Technology licensed to COMPANY under this Agreement as provided for in Article 5.5. Notwithstanding the foregoing, such ownership shall not be
construed to transfer to either PARTY ownership of or any license or other rights in or to any of such PARTY’S underlying Technology which may be included or embodied therein, or useful or necessary to use in connection with exploiting such
Invention. 


  

	5.3.	 Other Inventions. Except as set forth in Article 5.2, any other Invention developed hereunder solely by
COMPANY shall be COMPANY’S sole property and any other 



  
 12 














	 	
Invention developed hereunder solely by SELEXIS shall be SELEXIS’ sole property. The PARTIES do not anticipate that there will be any jointly developed Inventions hereunder, but if there are
any other such jointly developed Inventions which do not relate to either the SELEXIS Technology or the COMPANY Technology, such Inventions shall be owned jointly by COMPANY and SELEXIS (“Joint Inventions”). In the event any
such Joint Inventions arise, the PARTIES will use commercially reasonable efforts to cooperate to protect and/or exploit such Joint Inventions, including, without limitation, by sharing in costs incurred with protection of such Joint Inventions and
sharing in revenues generated by the use or sublicense of the Joint Inventions. 

  

	5.4.	 Notification. Each PARTY shall promptly notify the other PARTY of any Invention arising in connection
with this Agreement provided that COMPANY has no obligation to notify SELEXIS with respect to any COMPANY Inventions developed solely by COMPANY. 


  

	5.5.	 Improvements. In the event SELEXIS possesses, acquires, creates or is licensed (with the right to grant
a sublicense consistent with the terms of the Commercial License) any improvements to the SELEXIS Technology which are necessary or useful for COMPANY to use in connection with the use of the Cell Lines as licensed hereunder, such improvements shall
automatically be included in the SELEXIS Patent Rights and/or the SELEXIS Know-How and thereby disclosed and licensed at no extra cost to COMPANY in accordance with this Agreement; provided, however, that any
rights granted by the foregoing will be subject to COMPANY’S compliance with any bona fide obligations owed to Third Parties (with respect to which SELEXIS has notified COMPANY), including, without limitation, and royalty obligations owed to
Third Parties. 


  

	5.6.	 Third Party Patent Rights. SELEXIS covenants that if SELEXIS becomes aware that COMPANY’S use of
the SELEXIS Technology in accordance with the terms hereunder would or would likely infringe any Third Party proprietary rights, SELEXIS shall use its reasonable commercial efforts to resolve such potential infringement at SELEXIS’ cost to
ensure COMPANY’S freedom to continue to exercise the licenses granted under this Agreement, including without limitation by using its reasonable commercial efforts to obtain a license from the Third Party owner of the proprietary rights which
entitles SELEXIS to continue to grant the rights to COMPANY as provided for herein. Should such efforts not be successful, SELEXIS shall inform COMPANY in writing and thereafter either PARTY may terminate this Agreement with immediate effect, save
that SELEXIS shall not have such right if COMPANY agrees to waive any liability SELEXIS would otherwise have to COMPANY hereunder with respect to the infringement of such Third Party proprietary rights. The obligations set forth in this Article
relate solely to Third Party rights related specifically and solely to the SELEXIS Technology or SELEXIS Materials licensed hereunder, and do not apply with respect to any other technology or materials used by COMPANY at its discretion in connection
with its exercise of the license rights granted hereunder, and specifically exclude any such Third Party rights to the extent relating to the Licensed Product(s) produced by any Cell Lines hereunder. 



 

	5.7.	 Enforcement of SELEXIS Patent Rights. If, during the Term, either PARTY becomes aware of any
infringement or potential infringement of the SELEXIS Technology it shall promptly notify the other PARTY in writing and the PARTIES shall consult with each other to decide the best way to respond to such infringement or misuse, provided that
SELEXIS shall remain free to take any action as it deems fit in its sole discretion. 



  
 13 














	5.8.	 COMPANY Publications. COMPANY shall have the unrestricted right to publish or otherwise disclose the
results and data obtained by the practice of the SELEXIS Technology in accordance with the terms hereof, provided such publication or disclosure does not include any Confidential Information of SELEXIS. The name of SELEXIS shall be given proper
recognition in such publication(s) as scientifically appropriate. 


  

	5.9.	 Further Assurance. Each PARTY agrees to execute and do all things at the cost of the other PARTY (if not
specifically agreed otherwise) as the other PARTY may reasonably require to give that other PARTY the full benefit of the provisions of this Article 5. 


  

	6.	 Representations, Warranties, and Covenants 



 

	6.1.	 General. Except for the representations, warranties and covenants contained in this Article 6, the
PARTIES do not make any other representations, nor give any other warranties, express or implied, nor undertake to any other covenants. The PARTIES expressly exclude any and all other representations, warranties and covenants. 



 

	6.2.	 Representations and Warranties by the PARTIES. Each PARTY hereby represents and warrants to the other
PARTY that: 


  

	6.2.1.	 Corporate Power. It is duly organized and validly existing under the laws of the state (or country or
other jurisdiction, as the case may be) of its incorporation and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. 



 

	6.2.2.	 Due Authorization. It is duly authorized to execute and deliver this Agreement and to perform its
obligations hereunder and the persons executing this Agreement on its behalf have been duly authorized to do so by all requisite corporate actions. 


  

	6.2.3.	 Binding Agreement. This Agreement is a legal and valid obligation binding upon it and is enforceable in
accordance with its terms, except as enforceability may be limited by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable
principles and public policy. 


  

	6.2.4.	 No Conflicts. The execution, delivery and performance of this Agreement by it does not conflict with any
agreement, instrument or understanding, oral or written, to which it is a PARTY or by which it may be bound. 


  

	6.2.5.	 Intellectual Property Rights. Each PARTY represents that it has valid and sufficient arrangements and
agreements with its directors, officers and employees (which term shall include agents, consultants and subcontractors) such that ownership of intellectual property rights in and to any Inventions made by its directors, officers and employees vests
in such PARTY. 



  
 14 














	6.3.	 Additional Representations and Warranties by SELEXIS. SELEXIS hereby represents and warrants that, to
the best of its knowledge, as of the Effective Date: 


  

	6.3.1.	 There is no pending litigation asserting that the use of the SELEXIS Technology or the SELEXIS Know-How constitutes an infringement or misappropriation of any intellectual property rights of a Third Party; and 


  

	6.3.2.	 SELEXIS has the right in and to the SELEXIS Technology, SELEXIS
Know-How and the SELEXIS Patents to grant COMPANY the rights which are granted to COMPANY under this Agreement. 


  

	6.4.	 Additional Warranties by COMPANY. COMPANY hereby represents and warrants to SELEXIS that:



  

	6.4.1.	 There are no Third Party intellectual property rights or any other rights that may be asserted against SELEXIS
claiming that SELEXIS was or is directly infringing or is helping or assisting COMPANY in infringing such Third Party’s rights in connection with COMPANY’S exercise of the Commercial License granted by SELEXIS hereunder (except to the
extent that any such Third Party rights relate solely and specifically to the SELEXIS Technology and/or SELEXIS Materials), including, without limitation, the development, manufacture and commercialization of Licensed Products and/or Final Products
as permitted hereunder; and 


  

	6.4.2.	 As of the Effective Date, to the best of its knowledge, there is no litigation pending against COMPANY in
connection with the use or ownership of the Licensed Product, including, without limitation, the infringement or misappropriation of any intellectual property rights of a Third Party relating to the Licensed Product, and COMPANY has not received any
written claim that the use thereof infringes on any intellectual property rights of a Third Party or a request or demand from any Third Party for the licensing of any intellectual property rights to such Third Party in connection with the use of the
Licensed Product. 


  

	6.4.3.	 COMPANY will not knowingly misappropriate or infringe the intellectual property or other rights of any Third
Party in connection with its exercise of its licensed rights hereunder, including, without limitation, use of any SELEXIS Technology, Cell Line, or development, manufacture or sale of Licensed and/or Final Product hereunder, and understands and
agrees that SELEXIS will have no liability whatsoever for any such misappropriation or infringement to the extent they do not relate solely and specifically to the use of the SELEXIS Technology and/or SELEXIS Materials hereunder.



  

	6.5.	 Disclaimer of Warranties by SELEXIS. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT AND WITHOUT
LIMITING THE GENERALITY OF ARTICLE 6.1, SELEXIS DOES NOT MAKE NOR GIVE ANY REPRESENTATION OR WARRANTY TO COMPANY OF ANY NATURE, EXPRESS OR IMPLIED, THAT THE SELEXIS TECHNOLOGY WILL BE USEFUL FOR, OR ACHIEVE ANY PARTICULAR RESULTS AS A RESULT OF ANY
USE THEREOF BY SELEXIS OR BY COMPANY PURSUANT TO ANY LICENSE GRANTED TO COMPANY UNDER THIS AGREEMENT. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, 



  
 15 














	 	
SELEXIS SPECIFICALLY DISCLAIMS ANY WARRANTY OF NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 


 

	7.	 Liability and Indemnification 



 

	7.1.	 Indemnification by SELEXIS. During the Term of this Agreement and thereafter, SELEXIS hereby agrees to
save, defend and hold COMPANY, its Affiliates, and their respective officers, directors, employees, consultants and agents harmless from and against any and all Losses resulting directly from (i) any Third Party claim alleging that
Customer’s use of the SELEXIS technology and/or the SELEXIS Materials in strict accordance with the terms of this Agreement infringes or misappropriates such Third Party’s intellectual property or other property right (except to the extent
such claim relates to the use of the SELEXIS Technology and/or SELEXIS Materials in combination with any technologies or materials not supplied by SELEXIS or any modifications made by anyone other than SELEXIS to the SELEXIS Technology or SELEXIS
Materials); or (ii) any material breach of SELEXIS’ representations, warranties and covenants set forth in Article 6; except in each case to the extent that such Losses were caused by willful misconduct or gross negligence of COMPANY or
any of its Affiliates, Collaborators or Sublicensees. In the event COMPANY seeks indemnification under this Article 7.1. COMPANY shall notify SELEXIS of any claim as soon as reasonably practicable after it receives notice of the claim. COMPANY shall
allow SELEXIS to conduct and control the defense against the claim (including without limitation to settle the claim solely for monetary consideration), shall (at SELEXIS’ expense) execute and deliver such documents and other papers and take
such further actions as may be reasonably required to defend against the claim (including without limitation to settle the claim solely for monetary consideration) and shall (at SELEXIS’ expense) cooperate as requested by SELEXIS in the defense
of the claim, provided always that SELEXIS may not settle any such claim or otherwise consent to an adverse judgment or order in any relevant action or other proceeding which includes any admission as to liability or fault without the prior express
written consent of COMPANY, which consent will not be unreasonably withheld. 



  
 16 














	7.2.	 Indemnification by COMPANY. During the Term of this Agreement and thereafter, COMPANY hereby agrees to
save, defend and hold SELEXIS and its officers, directors, employees. consultants and agents harmless from and against any and all Losses resulting from (i) Third Party claims in connection with personal injury or damages to property caused by
the Licensed Products and/or Final Products, including, without limitation, any product liability claims however stated; (ii) Third Party claims relating to any use of the Cell Lines. SELEXIS Technology and/or SELEXIS Materials outside the
scope of the license granted herein or otherwise not in strict compliance with the terms hereof, or any use of the Cell Lines, SELEXIS Technology and/or SELEXIS Materials in conjunction with technology or materials not provided by SELEXIS, or any
modifications to the SELEXIS Technology and/or SELEXIS Materials (except in each of the foregoing cases to the extent SELEXIS is obligated to indemnify COMPANY pursuant to Article 8.1 above); or (iii) any material breach of COMPANY’S
representations, warranties and covenants set forth in Article 6; in each case, except to the extent that such Losses result from the willful misconduct or gross negligence of SELEXIS. In the event SELEXIS seeks indemnification under this Article,
SELEXIS shall notify COMPANY of any claim as soon as reasonably practicable after it receives notice of the claim. SELEXIS shall allow COMPANY to assume direction and control of the defense of the claim (including without limitation the right to
settle the claim solely for monetary consideration), and shall (at COMPANY’S expense) execute and deliver such documents and other papers and take such further actions as may be reasonably required to defend against the claim (including without
limitation to settle the claim solely for monetary consideration). SELEXIS shall (at COMPANY’S expense) cooperate as requested by COMPANY in the defense of the claim, provided always that COMPANY may not settle any such claim or otherwise
consent to an adverse judgment or order in any relevant action or other proceeding which includes any admission as to liability or fault without the prior express written consent of SELEXIS, which consent will not be unreasonably withheld.



  

	7.3.	 No Incidental or Consequential Damages. In no event shall either PARTY be responsible for any incidental
or consequential damages, including without limitation, lost profits or opportunities; provided that the foregoing shall in no event limit a PARTY’S indemnification obligation under Article 7.1 or Article 7.2. 



 

	7.4.	 Limitation of Liability. SELEXIS’ cumulative liability under this Agreement, whether in contract,
in tort, or otherwise, shall in no event exceed the aggregate consideration paid by COMPANY to SELEXIS under this Agreement. 


  

	8.	 Confidentiality 



 

	8.1.	 Non-disclosure. During the Term of this Agreement and for five
(5) years thereafter, each PARTY shall keep Confidential Information of the other PARTY confidential and shall not (i) use the other PARTY’S Confidential Information for any purpose not expressly permitted under this Agreement, nor
(ii) disclose the other PARTY’S Confidential information to any Person other than those of its agents, employees, and consultants (collectively, “Representatives”) who need to know such Confidential Information for a use
or purpose expressly permitted under this Agreement. Any such Representative who receives Confidential Information pursuant to this Article 8.1 shall be bound by written obligations of confidentiality and
non-use with respect to the Confidential Information that are no less stringent than the obligations set forth in this Agreement. 



  
 17 














	8.2.	 Exceptions. The confidentiality obligations set forth in Article 8.1 shall not apply to Confidential
Information that (i) is, or becomes, public information other than as the result of the violation of this Agreement or other act or omission by the receiving PARTY or its Representatives; (ii) was lawfully known to the receiving PARTY or
its Representatives without restriction on use or disclosure at the time of disclosure hereunder; (iii) is hereafter lawfully received by the receiving PARTY or its Representatives from a Third Party authorized to make such disclosure and
without restriction on use or disclosure; or (iv) is approved for release by prior written consent from the disclosing Party. 


  

	8.3.	 Authorized Disclosures. Notwithstanding any provision of this Agreement to the contrary,-each PARTY may
disclose Confidential Information of the other PARTY to the extent such disclosure is required by law, provided however that the receiving PARTY gives the disclosing PARTY reasonable prior written notice to enable the disclosing PARTY to take
appropriate measures to protect its Confidential Information and fully cooperates, subject to commercially reasonable efforts, with the disclosing PARTY to prevent or limit to the greatest extent possible the disclosure of Confidential Information.



  

	8.4.	 Use of Name. No right, express or implied, is granted to either PARTY by this Agreement to use in any
manner any trademark or trade name of the other PARTY including the names “ROAR Therapeutics” and “SELEXIS” without the prior written consent of the PARTY entitled to such trademark or trade name.



  

	9.	 Term and Termination 



 

	9.1.	 Term. This Agreement is effective as of the Effective Date. Unless earlier terminated pursuant to
Articles 9.2, 9.3 or 9.4 of this Agreement shall remain in full force and effect until expiration of the last-to-expire of the SELEXIS Patent Rights (the
“Term”). 


  

	9.2.	 Termination for Default. In addition to any other remedies which may be available at law or equity. in
the event of any material breach of this Agreement (the “Default”) by a PARTY (the “Defaulting Party”), the PARTY not in default (the “Non-Defaulting
Party”) shall have the right to give the Defaulting Party a written notice thereof (the “Notice of Default”), which must state the nature of the Default in reasonable details and request that the Defaulting
Party cure such Default within sixty (60) days. If such Default is not cured within sixty (60) days after receipt of a Notice of Default by the Defaulting Party or if such Default cannot be cured, the
Non-Defaulting Party may, at its sole discretion, terminate this Agreement by written notice effective upon receipt. 


  

	9.3.	 Termination for Bankruptcy. In the event that a PARTY shall become insolvent or make any arrangement
with its creditors or has a receiver or administrator appointed to the whole or any part of its assets or if an order shall be made or a resolution passed for its winding up unless such order or resolution is part of a scheme for its amalgamation or
reconstruction (the “Insolvent Party”), the other PARTY shall have the right, at its sole discretion, to serve immediate notice of termination of this Agreement, effective upon receipt. 



  
 18 














	9.4.	 Termination by COMPANY. COMPANY may terminate this Agreement at any time by giving sixty (60) days
written notice to SELEXIS. 


  

	9.5.	 Consequences of Expiration or Termination. 



 

	9.5.1.	 Termination of Licenses. In the event of a termination of this Agreement by COMPANY pursuant to Article
9.2 or 9.4 or by SELEXIS pursuant to Article 9.2 or 9.3, all and any rights and licenses granted under this Agreement shall terminate upon termination of this Agreement except for the licenses which have become perpetual pursuant to Article 3.1.3.



  

	9.5.2.	 SELEXIS Technology and Confidential Information. Upon termination of this Agreement under Article 9.2 or
Article 9.3 where COMPANY is the Insolvent Party, or Article 9.4, COMPANY shall dispose of all tangible embodiments of the SELEXIS Technology and SELEXIS Confidential Information, including without limitation the SELEXIS Materials and Cell Lines,
and render inaccessible or useless all electronic embodiments, of SELEXIS Confidential Information provided to COMPANY by SELEXIS hereunder, except that COMPANY may retain one copy of the SELEXIS Confidential Information delivered hereunder in its
secured legal files only for ensuring compliance with the terms of this Agreement. 


  

	9.5.3.	 COMPANY Confidential Information. Upon any expiration or termination of this Agreement, SELEXIS shall
dispose of all tangible embodiments, and render inaccessible or useless all electronic embodiments, of COMPANY Confidential Information provided to SELEXIS by COMPANY hereunder, except that SELEXIS may retain one copy of the COMPANY Confidential
Information delivered hereunder in its secured legal files only for ensuring compliance with the terms of this Agreement. 


  

	9.5.4.	 Accrued Obligations. Expiration or termination of this Agreement shall not relieve the PARTIES of any
obligation or liability accruing prior to such expiration or termination. 


  

	10.	 Miscellaneous 



 

	10.1.	 Assignment. Neither this Agreement nor any interest hereunder shall be assignable by either PARTY
without the prior written consent of the other PARTY; provided, that either PARTY may assign this Agreement and all of its rights and obligations hereunder, without such prior written consent, to an entity which acquires all or substantially all of
the business or assets of such PARTY (or the business or assets to which this Agreement pertains) whether by merger, consolidation, reorganization, acquisition, sale or otherwise; and COMPANY may assign this Agreement and all of its rights and
obligations hereunder, without such consent, to an Affiliate if COMPANY remains liable and responsible for the performance and observance of all of the Affiliate’s duties and obligations hereunder, and provided that such Affiliate is not a
Contract Manufacturing Organization. This Agreement shall be binding upon the successors and permitted assigns of the PARTIES and the name of a PARTY appearing herein shall be deemed to include the names of such PARTY’S successors and permitted
assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Article 10.1 shall be null and void. 



  
 19 














	10.2.	 Compliance with Governmental Obligations. Each PARTY shall comply, upon reasonable notice from the other
PARTY, with all governmental requests directed to either PARTY relating to this Agreement and provide all information and assistance necessary to comply with the governmental requests. 



 

	10.3.	 Counterparts. This Agreement may be executed in any number of counterparts, each of which need not
contain the signature of more than one PARTY but all such counterparts taken together shall constitute one and the same agreement, and may be executed through the use of facsimiles. 



 

	10.4.	 Dispute Resolution. The PARTIES agree that in the event of a dispute between them arising from,
concerning or in any way relating to this Agreement, the PARTIES shall undertake good faith efforts to resolve any such dispute, with the matter being referred at the request of either PARTY to the General Counsel (or chief legal officer) of each
PARTY and, if remaining unresolved after 30 days, then to the Chief Executive Officers of each PARTY (or their designees). If after 90 days of the matter first being referred to the General Counsel the PARTIES are unable to resolve such dispute,
either PARTY may seek any remedy available pursuant to Article 10.16. 


  

	10.5.	 Entire Agreement. This Agreement sets forth all of the covenants, promises, agreements, representations,
warranties, conditions and understandings between the PARTIES with respect to the subject matter hereof, and constitutes and contains the complete, final, and exclusive understanding and agreement of the PARTIES with respect to the subject matter
hereof, and cancels, supersedes and terminates all prior agreements and understanding between the PARTIES with respect to the subject matter hereof. There are no covenants, promises, agreements, representations, warranties, conditions or
understandings, whether oral or written, between the PARTIES other than as set forth herein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the PARTIES hereto unless reduced to writing and signed by
the respective authorized officers of the PARTIES. For the avoidance of doubt, to the extent of any inconsistency between this Agreement and the Services Agreement. the terms of this Agreement shall govern and prevail. 



 

	10.6.	 Force Majeure. Neither PARTY shall be liable to the other for loss, damages, default or delay due to
Force Majeure, provided that the PARTY affected by a case of Force Majeure gives prompt notice of such case to the other PARTY. The PARTY giving such notice shall thereupon be excused from its obligations hereunder as it is thereby disabled from
performing for so long as it is so disabled, provided, however, that such affected PARTY commences and continues to take reasonable and diligent actions to cure such cause: and provided further that if any Force Majeure delays or prevents the
performance of the obligations of either PARTY for a continuous period in excess of 30 days, the PARTY not affected shall then be entitled to terminate this Agreement, which termination shall be effective upon 10 days written notice to the affected
PARTY. Such a termination shall be irrevocable, except otherwise provided by the PARTIES and upon termination the provisions of Article 9.5 shall apply. 



  
 20 














	10.7.	 Further Actions. Each PARTY agrees to execute, acknowledge and deliver such further instruments, and to
do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 


  

	10.8.	 Independent Contractors. The relationship between SELEXIS and COMPANY created by this Agreement is one
of independent contractors and neither PARTY shall have the power or authority to bind or obligate the other PARTY except as expressly set forth in this Agreement. 



 

	10.9.	 Interpretation of Agreement. Articles and other descriptive headings used in this Agreement are for
reference purposes only and shall not constitute a part hereof or affect the meaning or interpretation of this Agreement. Whenever the context so requires, the use of the singular shall be deemed to include the plural and vice versa.



  

	10.10.	 License Obligations. Nothing in this Agreement imposes any obligation upon a PARTY to enter into any
other license or agreement with the other PARTY. 


  

	10.11.	 Notices. All notices and other communications required by this Agreement shall be in writing in the
English language and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by express courier service, to the
PARTIES at the following addresses (or at such other addresses that a PARTY specifies by like notice, provided, however, that notices of a change of address shall be effective only upon written receipt thereof): 



If to COMPANY, addressed to: 

ROAR Therapeutics 
 [***] 

San Diego, CA 92130 
 Attention:
                   Charles Prussak, Ph.D. 

Facsimile:                    [number] 

If to SELEXIS, addressed to: 

Selexis S.A. 
 18 Chemin des
Aulx 
 1228 Plan-les-Ouates 

Geneva, Switzerland 
 Attention:
                   Ms Sophie Vock (General Assistant) 

With a copy to:           CEO, Igor Fisch, Ph.D. 

Facsimile:                    +41 22 308-9361 

  
 21 














	10.12.	 Binding Effect. This Agreement shall be binding upon and inure solely to the benefit of COMPANY and
SELEXIS (and their permitted successors and assigns) and nothing in this Agreement (express or implied) is intended to or shall confer upon any Third Party any rights, benefits or remedies of any nature whatsoever under or by reason of this
Agreement. 


  

	10.13.	 Severability. If any term, covenant or condition of this Agreement or the application thereof to any
PARTY or circumstance shall, to any extent, be held to be invalid or unenforceable, then the remainder of this Agreement, or the application of such term, covenant or condition to PARTIES or circumstances other than those as to which it is held
invalid or unenforceable, shall not be affected thereby and each term, covenant or condition of this Agreement shall be valid and be enforced to the fullest extent permitted by applicable law. 



 

	10.14.	 Waiver. The failure on the part of a PARTY to exercise or enforce any rights conferred upon it hereunder
shall not be deemed to be a waiver of any such rights nor operate to bar the exercise or enforcement thereof at any time or times hereafter. 


  

	10.15.	 Survival. Articles 1, 3.4, 4, 5, 6, 7, 8, 9.5 and 10 shall survive any termination or expiration of this
Agreement in accordance with their terms. 


  

	10.16.	 Governing Law and Jurisdiction. This Agreement shall be governed by and construed in accordance with the
substantive laws of Switzerland, without regard to principles of conflict of laws. Any dispute arising out of or in connection with this Agreement shall be subject to the exclusive jurisdiction of the courts of Geneva, Switzerland.



 IN WITNESS WHEREOF, the PARTIES, having read the terms of this Agreement and intending to
be legally bound hereby, do hereby execute this agreement: 

  
 22 














							
	SELEXIS SA	    	ROAR Therapeutics
				
	Signature:	 	 /s/ Igor Fisch
	    	Signature:	  	 /s/Charles Prussak

				
	Place, Date:  	 	 6/6/14
	    	Place, Date:  	  	 5/28/14

				
	Name:	 	Igor Fisch	    	Name:	  	Charles Prussak, Ph.D.
				
	Title:	 	Chief Executive Officer	    	Title:	  	


  
 23 













 EXHIBIT 1 

SELEXIS PATENT RIGHTS 
 [***] 

  
 24 













 EXHIBIT 2 

LICENSED PRODUCT(S): 
 ROR-1 MAb aka UC-961 

  
 25